Cruzeiro do Sul Reports Record Profit and Margin Expansion in 3Q25

Higher student base and operational efficiency lift results; leverage falls to 0.7x EBITDA.

Nov 12, 2025 7:28 AM

By Brazil Stock Guide – Cruzeiro do Sul Educacional (CSED3) delivered its strongest quarter to date, posting a 78% jump in adjusted net income to R$113.3 million in the third quarter of 2025, as revenue, margins, and cash generation improved across all segments. Net revenue rose 11.1% year-on-year to R$694 million, driven by double-digit expansion in the digital and medical segments and stronger student retention. Adjusted EBITDA grew 28.5% to R$278 million, pushing the margin to a record 40.1%, from 34.6% a year earlier.

Operational performance and academic base growth
The company’s consolidated student base increased 9% year-on-year, led by a 13% rise in digital enrollments and 2% growth in on-campus students. Digital learning now represents 406,000 students, while the overall group serves more than 575,000 learners across 28 campuses and 1,570 learning hubs. The company highlighted the growing relevance of hybrid and live online programs, now 26% of the digital base, and strong retention rates — 92% for on-campus and 80% for digital courses. Average ticket prices rose 6.2% in face-to-face programs, supported by a higher share of health-related courses such as medicine and dentistry.

Financial efficiency and cash generation
Cruzeiro do Sul’s free cash flow to equity surged 35% in the quarter to R$221 million, representing 94% of EBITDA ex-IFRS 16, reflecting disciplined capital allocation and improved receivables management. The company cut its average collection period to 29 days, six fewer than a year earlier, and trimmed net debt by 40%, ending September with leverage at 0.7x EBITDA, the lowest in years. Investments fell 15% to R$32.8 million, while liquidity strengthened — cash reached R$840 million.

Management outlook and sector context
Executives said the performance reflects structural improvements in collections, technology, and operational management, alongside the maturation of new medical programs acquired or expanded in recent years. “Our strong cash conversion and EBITDA expansion demonstrate consistent execution and resilience,” the company noted in its management message.